The preventive effect of the serine protease inhibitor FUT-175 (nafamostat mesilate), a potent inhibitor of the complement system, against vasospasm was evaluated in 34 high risk patients with thick and diffuse subarachnoid hemorrhage (SAH) demonstrated by computed tomography corresponding to Fisher group 3. All patients underwent surgery within 96 hours following SAH and received the thromboxane A<SUB>2</SUB> synthetase inhibitor, OKY-046, as part of standard care. FUT-175 (40-160 mg/day) was administered during the initial 4 days following surgery. 455 patients treated without FUT-175 in the Nagasaki SAH Data Bank (non-FUT group) formed the control group. FUT-175 significantly de creased the incidence of symptomatic vasospasm in patients with severe neurological grade (Hunt and Hess grade 3, p &lt; 0.02; Hunt and Hess grade 4, p &lt; 0.02). The incidence of favorable outcome was 76.5% in the FUT group and 60.4% in the non-FUT group, but not statistically different. However, when patients of Hunt and Hess grade 5 were excluded, the FUT group had a significantly improved outcome (p &lt; 0.05). This study suggests that FUT-175 has an additive effect to OKY-046 in preventing vasospasm in high risk patients with severe SAH.
Introduction
Delayed ischemic neurological deficit (DIND) due to chronic cerebral vasospasm continues to be the major cause of poor clinical outcome in patients with subarachnoid hemorrhage (SAH). Many ther apeutic agents are in use to prevent or reduce vasospasm, 1, 2, 6, 14, 20, 21) but no definitive treatment has been identified. Recent experimental and clinical studies suggest that the inflammatory process is im portant in the pathogenesis of vasospasm. Histologi cal examination has demonstrated infiltration of neutrophils, lymphocytes, plasma cells, and macro phages into spastic arterial walls in humans") and ex perimental animal S22) as well as deposition of im munoglobulin G and the complement component C3.9) Furthermore, within 48 hours of SAH, sig nificant activation of the complement components C3 and C4 occurred in the cerebrospinal fluid (CSF) space of patients who later developed DIND.15) The elevated levels of these complement components in the early post-SAH period fell rapidly within a few days.") Also, a high serum concentration of im munocomplexes precedes the onset of vasospasm.18) These observations support the hypothesis that the inflammatory process, particularly activation of the complement system, may trigger vasospasm, and therefore treatment with FUT-175 (nafamostat mesi late), an inhibitor of the complement system, 1,12) in the very early post-SAH period will prevent vasospasm.23,14) The amount of clot in the basal cistern is a risk factor for chronic vasospasm3°4) and the incidence of symptomatic vasospasm is greater than 50% in patients with thick SAH on computed tomography (CT). 4, 5) tion to a thromboxane A2 (TXA2) synthetase inhibi tor OKY-046 (sodium ozagrel) for the treatment of high risk patients with thick and diffuse SAH on CT.
Materials and Methods
This study included 34 patients with diffuse and thick clot in the subarachnoid space (Fisher group 33)) who underwent clipping of the aneurysm within 96 hours of first onset of symptoms between 1990 and 1995 (FUT group). Patients with intracerebral or intraventricular clot as well as diffuse and thick clot in the subarachnoid space were also included. In formed consent was obtained from the patients or guardians. Continuous intravenous infusion of OKY-046 (80 mg/day) was carried out from the day following surgery to day 14 of SAH. FUT-175 (40 160 mg/day, divided into 2-4 doses) was ad ministered intravenously for the initial 4 days follow ing surgery. The rate of infusion was approximately 20 mg/60 min.
The aim of the present study was to evaluate the ef fect of additional use of FUT-175 to OKY-046 for the prevention of vasospasm. Therefore, 455 patients classified in Fisher group 3, and who underwent sur gery within 96 hours following SAH, followed by treatment with OKY-046 from the Nagasaki SAH Data Bank formed the control group (non-FUT group). Patients who had new neurological deficits immediately after the operation were excluded. Other treatments for vasospasm such as hyperten sive hypervolemic therapy, low molecular weight dextran, mannitol, and glycerol were allowed. Calci um antagonist to control blood pressure was also al lowed.
However, aggressive removal of subarachnoid clots during surgery was not usually employed in either the FUT group or the non-FUT group. 
Results
Administration of FUT-175 significantly decreased the overall incidence of symptomatic vasospasm in cluding permanent and transient vasospasm (p < 0.001, Table 2 ). Administration of FUT-175 sig nificantly decreased the incidence of symptomatic vasospasm in patients with Hunt and Hess") grade 3 (p < 0.02) and grade 4 (p < 0.02). The incidence of symptomatic vasospasm in patients with grade 1 plus 2 was also decreased but no statistical differ ence was found.
Patients who had received FUT-175 tended to achieve a more favorable outcome (good recovery or moderate disability), but this difference was not statistically significant (Table 3) . However, if patients with grade 5 who suffered from serious neu rological deficit caused by the direct effect of SAH were excluded, 26 of 32 patients in the FUT group (81.3%) showed favorable outcome, which was sig nificantly higher than the 62.0% in the non-FUT group (p < 0.05).
Two patients were given less than 80 mg/day of FUT-175 in the initial study, but both developed symptomatic vasospasm (Fig. 1 ). FUT-175 was ini tiated on day 2 of SAH in one patient and on day 3 of SAH in another. In the subsequent study, a dose of 80 mg/day or higher was used. The incidence of symptomatic vasospasm decreased from 29.4% to 25% in the FUT group after exclusion of these two patients. Only three of 13 patients treated with 80 mg/day FUT-175 exhibited symptomatic vasospasm, whereas five of 19 patients who received more than 80 mg/day of FUT-175 developed symptomatic vasospasm.
This difference was not significant. The significance of the timing of FUT therapy was also evaluated in patients treated with 80 mg/day or more (Fig. 2) . When FUT therapy was started within day 2 of SAH, the incidence of symptomatic vasospasm was 16.7%, but increased to 50% by late initiation of FUT therapy (start at day 3 or 4 after SAH). However, no statistical difference was demonstrat ed between these two groups. 
Commentary
This paper discusses the interesting part possibly played by inflammatory factors in the development of delayed vasospasm, presenting both histological and biochemical evidence in support. The use of FUT-175, an inhibitor of the complement system, has arisen from this. The results presented do go some way towards supporting this hypothesis, with a reduced in cidence of symptomatic vasospasm in the group receiving FUT-175 as well as OKY-046, and an im proved three-month outcome in this group for grade 1-4 patients. However, I don't think one can be more definite than that at present, since this was not a randomized study, but the FUT-175 patients were compared with controls from presumably a number of centers in the district (concurrent or historical?). Also, even though the controls were also Fisher grade 3, the incidence of delayed spasm of more than 57% seems rather high. Confirmation of spasm by transcranial Doppler or an giography in both groups would have been useful. In the past, many different treatments for delayed vasospasml) have appeared very promising when first used on a small number of patients without ran domized controls receiving exactly the same back ground treatment, and then later controlled trials would show no effect. I think it very important that serious consideration be given to such a study at this stage in the development of FUT-175.
